Pieris Pharmaceuticals, Inc. (PIRS) Stock Analysis

Pieris Pharmaceuticals, Inc. (PIRS) Healthcare & Pipeline Overview

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in Anticalin-based therapies for respiratory and immuno-oncology indications. With a pipeline featuring programs in Phase II trials and strategic partnerships with AstraZeneca and Seagen, Pieris aims to address unmet medical needs through innovative protein engineering.

What Is the Investment Thesis for PIRS?

Pieris Pharmaceuticals presents a high-risk, high-reward investment opportunity. The company's Anticalin technology offers a novel approach to drug development, with potential advantages in terms of target specificity and manufacturability. Key value drivers include the successful advancement of PRS-060/AZD1402 through Phase II trials for asthma and the progress of Cinrebafusp alfa in gastric cancer. The company's collaborations with AstraZeneca and Seagen provide financial stability and validation of its technology. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's market cap is approximately $0.02 billion as of May 9, 2026, reflecting the early stage of its pipeline and the inherent uncertainties in drug development.

Based on FMP financials and quantitative analysis

PIRS Key Highlights

PRS-060/AZD1402 is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases.

• PRS-220 is an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis.
• Cinrebafusp alfa is a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers.
• Collaboration agreements with AstraZeneca AB and Seagen Inc. provide financial support and validation for Pieris's technology.
• Market capitalization of $18.0M reflects the company's clinical-stage status and potential for future growth.

Who Are PIRS's Competitors?

PIRS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PIRS's Key Strengths?

Novel Anticalin technology platform.

• Clinical-stage pipeline with multiple drug candidates.
• Strategic partnerships with major pharmaceutical companies.
• Strong intellectual property portfolio.

What Are PIRS's Weaknesses?

Limited financial resources.

• Dependence on partnerships for funding and development.
• High risk of clinical trial failures.
• Small number of employees.

What Could Drive PIRS Stock Higher?

Phase II clinical trial results for PRS-060/AZD1402 in asthma.

• Phase 1 clinical trial results for PRS-344/S095012 in immuno-oncology.
• Progression of PRS-220 into clinical development for idiopathic pulmonary fibrosis.
• Potential for new strategic partnerships and collaborations.

What Are the Key Risks for PIRS?

Financial-distress signal — its Altman Z-Score of 0.22 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-56.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for drug candidates.
• Regulatory delays or rejections.
• Competition from established pharmaceutical companies.
• Dependence on partnerships for funding and development.
• Patent expirations and intellectual property challenges.

What Are the Growth Opportunities for PIRS?

• Expansion of PRS-060/AZD1402 into additional indications: The success of PRS-060/AZD1402 in asthma could pave the way for its development in other inflammatory diseases, such as atopic dermatitis and eosinophilic esophagitis. These indications represent significant market opportunities, with a combined market size estimated at billions of dollars. The timeline for expansion would depend on the results of ongoing clinical trials and regulatory approvals.
• Advancement of Cinrebafusp alfa in HER2-expressing cancers: Cinrebafusp alfa, Pieris's 4-1BB/HER2 bispecific, has the potential to address unmet needs in HER2-expressing gastric cancers. Positive results from Phase 1 clinical trials could lead to further development in other HER2-positive tumors, such as breast cancer. The market for HER2-targeted therapies is substantial, with ongoing innovation and competition.
• Development of PRS-220 for idiopathic pulmonary fibrosis (IPF): PRS-220, an inhaled Anticalin targeting connective tissue growth factor, offers a novel approach to treating IPF. The IPF market is growing due to the increasing prevalence of the disease and the limited treatment options available. Successful clinical trials could position PRS-220 as a valuable therapy for IPF patients.
• Strategic partnerships and collaborations: Pieris has a track record of establishing strategic partnerships with major pharmaceutical companies, such as AstraZeneca and Seagen. These collaborations provide financial support, validation of its technology, and access to new markets. Future partnerships could further expand the reach of Pieris's Anticalin platform and accelerate the development of its pipeline.
• Expansion of the Anticalin platform into new therapeutic areas: Pieris's Anticalin technology has the potential to be applied to a wide range of therapeutic areas beyond respiratory diseases and immuno-oncology. The company could explore opportunities in areas such as autoimmune diseases, metabolic disorders, and infectious diseases. This would require further research and development efforts, but could significantly expand the long-term potential of the company.

What Are PIRS's Competitive Advantages?

• Proprietary Anticalin technology platform: Pieris's Anticalin technology offers a differentiated approach to drug development, with potential advantages in terms of target specificity and manufacturability.
• Strong intellectual property portfolio: Pieris has a portfolio of patents protecting its Anticalin technology and drug candidates.
• Strategic partnerships with major pharmaceutical companies: Collaborations with AstraZeneca and Seagen provide financial support, validation of its technology, and access to new markets.
• Clinical-stage pipeline: Pieris has several drug candidates in clinical development, increasing the likelihood of successful product launches.

What Does PIRS Do?

Pieris Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Boston, Massachusetts. The company is focused on discovering and developing Anticalin-based drugs, a novel class of therapeutic proteins derived from lipocalins. These low molecular-weight proteins are engineered to target specific disease pathways with high affinity and specificity. Pieris's pipeline includes drug candidates targeting respiratory diseases, such as asthma and idiopathic pulmonary fibrosis (IPF), as well as immuno-oncology programs focused on enhancing anti-tumor immunity. Their lead respiratory candidate, PRS-060/AZD1402, is in Phase II clinical trials for asthma, targeting the IL-4Ra pathway. PRS-220, an inhaled Anticalin, is being developed for IPF, targeting connective tissue growth factor. In immuno-oncology, Cinrebafusp alfa, a 4-1BB/HER2 bispecific, is in development for HER2-expressing gastric cancers. Pieris also has ongoing collaborations with major pharmaceutical companies, including AstraZeneca, Seagen, and Eli Lilly, to advance its Anticalin technology across various therapeutic areas. These partnerships provide financial support and validation for Pieris's platform, while also expanding the potential applications of Anticalin-based therapies.

What Products and Services Does PIRS Offer?

• Discovers and develops Anticalin-based drugs.
• Develops Anticalin proteins, low molecular-weight therapeutic proteins derived from lipocalins.
• Focuses on treatments for respiratory diseases and immuno-oncology.
• Conducts Phase II clinical trials for PRS-060/AZD1402 targeting IL-4Ra for asthma.
• Develops PRS-220, an oral inhaled Anticalin protein for idiopathic pulmonary fibrosis.
• Advances Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for HER2-expressing gastric cancers.
• Collaborates with pharmaceutical companies like AstraZeneca and Seagen.

How Does PIRS Make Money?

• Develops and patents novel Anticalin-based drug candidates.
• Conducts preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
• Partners with pharmaceutical companies through licensing and collaboration agreements to advance drug development and commercialization.
• Receives upfront payments, milestone payments, and royalties from its partnerships.
• Potentially commercializes its own products independently or through partnerships.

What Industry Does PIRS Operate In?

Pieris Pharmaceuticals operates in the competitive biotechnology industry, characterized by high R&D costs, lengthy development timelines, and regulatory scrutiny. The market for respiratory disease therapeutics is substantial, driven by the increasing prevalence of asthma and IPF. The immuno-oncology market is also rapidly growing, with significant unmet needs in the treatment of various cancers. Pieris's Anticalin technology offers a differentiated approach to drug development, potentially providing advantages over traditional antibodies and small molecules. Competition includes major pharmaceutical companies and other biotech firms developing therapies for similar indications.

Who Are PIRS's Key Customers?

• Patients suffering from respiratory diseases such as asthma and idiopathic pulmonary fibrosis.
• Patients with HER2-expressing gastric cancers.
• Pharmaceutical companies seeking to license or collaborate on the development of novel therapeutics.
• Healthcare providers who prescribe and administer Pieris's drugs.
• Clinical trial participants who contribute to the development of Pieris's drug candidates.

Company Profile

Pieris Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Stephen S. Yoder. PIRS has traded publicly since 2015.

How Pieris Pharmaceuticals, Inc. Is Valued

Pieris Pharmaceuticals, Inc. carries a market capitalization of $18.0M, placing it in the micro-cap category.

Return on equity for Pieris Pharmaceuticals, Inc. stands at -56.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.7%, showing how much profit it generates from its asset base. A current ratio of 28.88 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -27.7%, the inverse of the P/E and a quick read on earnings relative to price.

Pieris Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.22 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Pieris Pharmaceuticals, Inc. revenue of about $0 for fiscal 2026, with EPS near $-24.80.

PIRS Financials

PIRS Latest News

PIRS Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources